Cargando…

Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer’s disease

BACKGROUND: Biomarkers that can track disease onset and progression in autosomal dominant Alzheimer’s disease (ADAD) are needed. We investigate whether serum neurofilament light (NfL) concentration is associated with clinical and cerebrospinal fluid (CSF) markers in ADAD. We also evaluate serum NfL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sánchez-Valle, Raquel, Heslegrave, Amanda, Foiani, Martha S., Bosch, Beatriz, Antonell, Anna, Balasa, Mircea, Lladó, Albert, Zetterberg, Henrik, Fox, Nick C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6215337/ https://www.ncbi.nlm.nih.gov/pubmed/30390718 http://dx.doi.org/10.1186/s13195-018-0439-y

Ejemplares similares

Neurofilament light chain as a potential biomarker for monitoring neurodegeneration in X-linked adrenoleukodystrophy
por: Weinhofer, Isabelle, et al.
Publicado: (2021)

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome
por: Strydom, Andre, et al.
Publicado: (2018)

Plasma Markers of Neurodegeneration Are Raised in Friedreich’s Ataxia
por: Zeitlberger, Anna M., et al.
Publicado: (2018)

Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration
por: Weston, Philip S.J., et al.
Publicado: (2017)

Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease
por: Lewczuk, Piotr, et al.
Publicado: (2018)

Association of plasma neurofilament light chain with disease activity in chronic inflammatory demyelinating polyradiculoneuropathy
por: Kapoor, Mahima, et al.
Publicado: (2022)

Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer’s disease
por: Weston, Philip S. J., et al.
Publicado: (2019)

Plasma amyloid-β ratios in autosomal dominant Alzheimer’s disease: the influence of genotype
por: O'Connor, Antoinette, et al.
Publicado: (2021)

Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer’s disease
por: Andersson, Emelie, et al.
Publicado: (2020)

Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease
por: Schultz, Stephanie A., et al.
Publicado: (2020)

Plasma biomarker profiles in autosomal dominant Alzheimer’s disease
por: Johansson, Charlotte, et al.
Publicado: (2023)

The APOE4 effect: structural brain differences in Alzheimer's disease according to the age at symptom onset
por: Forno, Gonzalo, et al.
Publicado: (2022)

Longitudinal brain atrophy and CSF biomarkers in early-onset Alzheimer’s disease
por: Contador, José, et al.
Publicado: (2021)

Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease
por: Moscoso, Alexis, et al.
Publicado: (2021)

Contribution of CSF biomarkers to early‐onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures
por: Falgàs, Neus, et al.
Publicado: (2020)

Hippocampal atrophy has limited usefulness as a diagnostic biomarker on the early onset Alzheimer's disease patients: A comparison between visual and quantitative assessment
por: Falgàs, Neus, et al.
Publicado: (2019)

Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease
por: Pera, Marta, et al.
Publicado: (2012)

Screening for neurodegeneration in Langerhans cell histiocytosis with neurofilament light in plasma
por: Sveijer, Malin, et al.
Publicado: (2022)

Autosomal dominant mitochondrial membrane protein‐associated neurodegeneration (MPAN)
por: Gregory, Allison, et al.
Publicado: (2019)

Alzheimer’s Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint
por: Alawode, Deborah O. T., et al.
Publicado: (2022)

Plasma Neurofilament Light as a Biomarker of Neurological Involvement in Wilson's Disease
por: Shribman, Samuel, et al.
Publicado: (2020)

Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease
por: Bateman, Randall J, et al.
Publicado: (2011)

Early‐onset Alzheimer's disease shows a distinct neuropsychological profile and more aggressive trajectories of cognitive decline than late‐onset
por: Tort‐Merino, Adrià, et al.
Publicado: (2022)

CSF synaptic protein concentrations are raised in those with atypical Alzheimer’s disease but not frontotemporal dementia
por: Clarke, Mica T. M., et al.
Publicado: (2019)

Disease duration in autosomal dominant familial Alzheimer disease: A survival analysis
por: Pavisic, Ivanna M., et al.
Publicado: (2020)

Neurofilament Light in CSF and Plasma Is a Marker of Neuronal Damage in HTLV-1–Associated Myelopathy and Correlates With Neuroinflammation
por: Rosadas, Carolina, et al.
Publicado: (2021)

Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP
por: Chiotis, Konstantinos, et al.
Publicado: (2023)

Thalamic nuclei changes in early and late onset Alzheimer's disease
por: Forno, Gonzalo, et al.
Publicado: (2023)

Molecular biomarkers of Alzheimer's disease: progress and prospects
por: Lashley, Tammaryn, et al.
Publicado: (2018)

Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers
por: Ashton, Nicholas J., et al.
Publicado: (2019)

In the blood: biomarkers for amyloid pathology and neurodegeneration in Alzheimer’s disease
por: Toombs, Jamie, et al.
Publicado: (2020)

First presentation with neuropsychiatric symptoms in autosomal dominant Alzheimer’s disease: the Dominantly Inherited Alzheimer’s Network Study
por: O'Connor, Antoinette, et al.
Publicado: (2023)

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Neurofilament light predicts neurological outcome after subarachnoid haemorrhage
por: Garland, Patrick, et al.
Publicado: (2021)

Plasma glial fibrillary acidic protein and neurofilament light chain, but not tau, are biomarkers of sports-related mild traumatic brain injury
por: Laverse, Etienne, et al.
Publicado: (2020)

Saliva Neurofilament Light Chain Is Not a Diagnostic Biomarker for Neurodegeneration in a Mixed Memory Clinic Population
por: Gleerup, Helena Sophia, et al.
Publicado: (2021)

Classifying Alzheimer's disease and frontotemporal dementia using machine learning with cross‐sectional and longitudinal magnetic resonance imaging data
por: Pérez‐Millan, Agnès, et al.
Publicado: (2023)

Neurofilament light chain: defining the analyte
por: Leckey, Claire A., et al.
Publicado: (2022)

Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease
por: Raket, Lars Lau, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r42mtksf7hih9q3865jgpgl08f